Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: LGND stock price vs MHK: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MHK's multiple
Needs MHK P/E.
Implied fair value · at LGND's multiple
Needs LGND P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: LGND FY 2025 (ended Dec 31, 2025) · MHK FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 19.90x · EV / EBITDA 33.29x
Capital structure 80% equity / 20% debt · EV / Revenue 0.98x · EV / EBITDA 8.23x
MHK carries the larger enterprise value at $10.52B against $5.33B; MHK trades on the lower EV / Revenue multiple (0.98x vs 19.90x); MHK on the lower EV / EBITDA (8.23x vs 33.29x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
LIGAND PHARMACEUTICALS INCORPORATED · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
MOHAWK INDUSTRIES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.37x
0.28x
Net debt / EBITDA
Leverage against operating earnings
-2.24x
1.15x
Cash and equivalents
Liquid reserves on the balance sheet
$733.52M
$856.10M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Royalty Pharma plc
LGND vs RPRX
Sarepta Therapeutics, Inc.
LGND vs SRPT
INCYTE CORP
LGND vs INCY
EXELIXIS, INC.
LGND vs EXEL
INTERFACE INC
LGND vs TILE
MASCO CORP /DE/
LGND vs MAS
RPM INTERNATIONAL INC/DE/
LGND vs RPM
MARTIN MARIETTA MATERIALS INC
LGND vs MLM
Vulcan Materials CO
LGND vs VMC
$374.08M
$2.33B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
